{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:44:06Z","timestamp":1772163846907,"version":"3.50.1"},"reference-count":42,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Finnish Foundation","award":["4706116"],"award-info":[{"award-number":["4706116"]}]},{"name":"ERC","award":["681219"],"award-info":[{"award-number":["681219"]}]},{"name":"HiLIFE HiPOC","award":["115422"],"award-info":[{"award-number":["115422"]}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"crossref","award":["4705796"],"award-info":[{"award-number":["4705796"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Academy of Finland and Digital Precision Cancer Medicine Flagship iCAN"},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["1317206"],"award-info":[{"award-number":["1317206"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HiLIFE Fellow","award":["797011004"],"award-info":[{"award-number":["797011004"]}]},{"DOI":"10.13039\/501100004155","name":"Magnus Ehrnrooth Foundation","doi-asserted-by":"crossref","award":["4706235"],"award-info":[{"award-number":["4706235"]}],"id":[{"id":"10.13039\/501100004155","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,6,15]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intratumoral BCG therapy, one of the earliest immunotherapies, can lead to infiltration of immune cells into a treated tumor. However, an increase in the number of BCG-induced tumor-specific T cells in the tumor microenvironment could lead to enhanced therapeutic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we have developed a novel cancer vaccine platform based on BCG that can broaden BCG-induced immune responses to include tumor antigens. By physically attaching tumor-specific peptides onto the mycobacterial outer membrane, we were able to induce strong systemic and intratumoral T cell-specific immune responses toward the attached tumor antigens. These therapeutic peptides can be efficiently attached to the mycobacterial outer membrane using a poly-lysine sequence N-terminally fused to the tumor-specific peptides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using two mouse models of melanoma and a mouse model of colorectal cancer, we observed that the antitumor immune responses of BCG could be improved by coating the BCG with tumor-specific peptides. In addition, by combining this novel cancer vaccine platform with anti-programmed death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy, the number of responders to anti-PD-1 immunotherapy was markedly increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study shows that intratumoral BCG immunotherapy can be improved by coating the bacteria with modified tumor-specific peptides. In addition, this improved BCG immunotherapy can be combined with ICI therapy to obtain enhanced tumor growth control. These results warrant clinical testing of this novel cancer vaccine platform.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-002707","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:34:18Z","timestamp":1626352458000},"page":"e002707","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Novel personalized cancer vaccine platform based on Bacillus Calmette-Gu\u00e8rin"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9678-2614","authenticated-orcid":false,"given":"Erkko","family":"Yl\u00f6sm\u00e4ki","sequence":"first","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-3018","authenticated-orcid":false,"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Martins","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-4310","authenticated-orcid":false,"given":"Sara","family":"Feola","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Hamdan","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Chiaro","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Yl\u00f6sm\u00e4ki","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"Valo Therapeutics Oy, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Valo Therapeutics Oy, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapani","family":"Viitala","sequence":"additional","affiliation":[{"name":"Pharmaceutical Biophysics Research Group, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt Ltd, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland"},{"name":"Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University 24 Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"2025100315145808000_9.7.e002707.1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"2025100315145808000_9.7.e002707.2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/13543784.2019.1655730","article-title":"Current advances in BCG-unresponsive non-muscle invasive bladder cancer","volume":"28","author":"Tse","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2025100315145808000_9.7.e002707.3","first-page":"158","article-title":"Immunological factors which influence response to immunotherapy in malignant melanoma","volume":"68","author":"Morton","year":"1970","journal-title":"Surgery"},{"key":"2025100315145808000_9.7.e002707.4","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197410000-00029"},{"key":"2025100315145808000_9.7.e002707.5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0051"},{"key":"2025100315145808000_9.7.e002707.6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CJI.0000000000000098","article-title":"Treatment of in-transit melanoma with intralesional bacillus Calmette-Gu\u00e9rin (BCG) and topical imiquimod 5% cream: a report of 3 cases","volume":"38","author":"Kibbi","year":"2015","journal-title":"J Immunother"},{"key":"2025100315145808000_9.7.e002707.7","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31827457bd"},{"key":"2025100315145808000_9.7.e002707.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15"},{"key":"2025100315145808000_9.7.e002707.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00061","article-title":"Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Gu\u00e9rin","volume":"7","author":"Yang","year":"2017","journal-title":"Front Oncol"},{"key":"2025100315145808000_9.7.e002707.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004421117"},{"key":"2025100315145808000_9.7.e002707.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017"},{"key":"2025100315145808000_9.7.e002707.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24951"},{"key":"2025100315145808000_9.7.e002707.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110814108"},{"key":"2025100315145808000_9.7.e002707.14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100315145808000_9.7.e002707.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01903.x"},{"key":"2025100315145808000_9.7.e002707.16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform","volume":"20","author":"Yl\u00f6sm\u00e4ki","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"2025100315145808000_9.7.e002707.17","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20157"},{"key":"2025100315145808000_9.7.e002707.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914879107"},{"key":"2025100315145808000_9.7.e002707.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1403078111"},{"key":"2025100315145808000_9.7.e002707.20","first-page":"185","article-title":"Origins of BCG surface charge: effect of ionic strength and chemical modifications on zeta potential of Mycobacterium bovis BCG, Tice substrain, cells","volume":"70","author":"Kristensen","year":"1992","journal-title":"Microbios"},{"key":"2025100315145808000_9.7.e002707.21","first-page":"191","article-title":"The surface charge of cells of Mycobacterium bovis BCG vaccine, Tice substrain","volume":"53","author":"Zhang","year":"1988","journal-title":"Microbios"},{"key":"2025100315145808000_9.7.e002707.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(88)91043-4"},{"key":"2025100315145808000_9.7.e002707.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.1989.tb00475.x"},{"key":"2025100315145808000_9.7.e002707.24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/jvi.43.1.26-36.1982","article-title":"Organization, distribution, and stability of endogenous ecotropic murine leukemia virus DNA sequences in chromosomes of Mus musculus","volume":"43","author":"Jenkins","year":"1982","journal-title":"J Virol"},{"key":"2025100315145808000_9.7.e002707.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.06.008"},{"key":"2025100315145808000_9.7.e002707.26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jnci\/56.4.803","article-title":"Inconsistent response of B16 melanoma to BCG immunotherapy","volume":"56","author":"Kreider","year":"1976","journal-title":"J Natl Cancer Inst"},{"key":"2025100315145808000_9.7.e002707.27","doi-asserted-by":"publisher","DOI":"10.1038\/2281210a0"},{"key":"2025100315145808000_9.7.e002707.28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CJI.0000000000000208","article-title":"Brief communication; a heterologous oncolytic Bacteria-Virus prime-boost approach for anticancer vaccination in mice","volume":"41","author":"Aitken","year":"2018","journal-title":"J Immunother"},{"key":"2025100315145808000_9.7.e002707.29","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.154"},{"key":"2025100315145808000_9.7.e002707.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1531159"},{"key":"2025100315145808000_9.7.e002707.31","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1991.7.615"},{"key":"2025100315145808000_9.7.e002707.32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512329"},{"key":"2025100315145808000_9.7.e002707.33","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3892\/mmr.2015.3770","article-title":"Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice","volume":"12","author":"Li","year":"2015","journal-title":"Mol Med Rep"},{"key":"2025100315145808000_9.7.e002707.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003790"},{"key":"2025100315145808000_9.7.e002707.35","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12308"},{"key":"2025100315145808000_9.7.e002707.36","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"2025100315145808000_9.7.e002707.37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamaoncol.2020.6142","article-title":"Pembrolizumab for non-muscle-invasive bladder cancer-a costly therapy in search of evidence","volume":"7","author":"Gill","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025100315145808000_9.7.e002707.38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100315145808000_9.7.e002707.39","doi-asserted-by":"crossref","unstructured":"Tran V , Liu J , Behr MA . BCG vaccines. Microbiol Spectr 2014;2.doi:10.1128\/microbiolspec.MGM2-0028-2013","DOI":"10.1128\/microbiolspec.MGM2-0028-2013"},{"key":"2025100315145808000_9.7.e002707.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.12.010"},{"key":"2025100315145808000_9.7.e002707.41","doi-asserted-by":"publisher","DOI":"10.1159\/000355628"},{"key":"2025100315145808000_9.7.e002707.42","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/all.14345","article-title":"Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?","volume":"75","author":"Gursel","year":"2020","journal-title":"Allergy"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:15:06Z","timestamp":1759529706000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,15]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/jitc-2021-002707"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002707","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.05.434062","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}